01/31/2020 | CureVac AG | News

CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019

TÜBINGEN, Germany/ BOSTON, USA / OSLO, Norway January 31, 2020 – CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, and the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private partnership set up to accelerate development of vaccines against emerging infectious diseases, today announced a collaboration to develop a vaccine against the new coronavirus nCoV-2019. The aim of the cooperation is to safely advance vaccine candidates into clinical testing as quickly as possible. The agreement will build on the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and includes additional initial funding of up to $8.3 million by CEPI for accelerated vaccine development, manufacturing and clinical tests.

Further information


CureVac Media Contact
Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577

CEPI Media Contacts
Rachel Grant, Director of Communications and Advocacy, CEPI
Tel: +44(0)7891249190
Email: rachel.grant@cepi.net

Mario Christodoulou, Communications and Advocacy Manager, CEPI
Tel: +44 (0) 7979300222
Email: Mario.christodoulou@cepi.net

Jodie Rogers, Communications Officer, CEPI
Tel: +44(0)79 793 57 459
Email: jodie.rogers@cepi.net

Federal Ministry of Education and Research Media Contacts
Svenja Jambo, Spokeswoman
Tel: +49 30 18 57-5943
Email: Svenja.Jambo@bmbf.bund.de